Literature DB >> 5677720

Acute muscular syndrome associated with administration of clofibrate.

T Langer, R I Levy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5677720     DOI： 10.1056/NEJM196810172791604

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  38 in total

1.  Modulation of the gating of CIC-1 by S-(-) 2-(4-chlorophenoxy) propionic acid.

Authors:  E C Aromataris; D S Astill; G Y Rychkov; S H Bryant; A H Bretag; M L Roberts
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 2.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

3.  Clofibrate-induced myopathy in the rat.

Authors:  H Teräväinen; A Larsen; M Hillbom
Journal:  Acta Neuropathol       Date:  1977-08-16       Impact factor: 17.088

4.  Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation.

Authors:  N M Fisher; K Meksawan; A Limprasertkul; P J Isackson; D R Pendergast; G D Vladutiu
Journal:  J Inherit Metab Dis       Date:  2007-04-05       Impact factor: 4.982

5.  The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.

Authors:  A J Williams; F Baker; J Walls
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

6.  Paradoxical effects of clofibrate on liver and muscle metabolism in rats. Induction of myotonia and alteration of fatty acid and glucose oxidation.

Authors:  H S Paul; S A Adibi
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

Review 7.  Adverse effects of drugs on muscle.

Authors:  F L Mastaglia
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

8.  Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians.

Authors: 
Journal:  Br Med J       Date:  1971-12-25

9.  [Drug treatment of primary hyperlipoproteinemia (author's transl)].

Authors:  G Klose; R Mordasini; G Middelhoff; J Augustin; H Greten
Journal:  Klin Wochenschr       Date:  1978-02-01

10.  Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids.

Authors:  Paul S Phillips; Theodore P Ciaraldi; Dong-Lim Kim; M Anthony Verity; Tanya Wolfson; Robert R Henry
Journal:  Endocrine       Date:  2008-12-03       Impact factor: 3.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.